Why Carlsmed, Inc.’s (CARL) Stock Is Up 5.01%
As of Friday, October 02, Carlsmed, Inc.’s CARL share price has surged by 5.01%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
Commentary & Analysis
Why Carlsmed, Inc.’s (CARL) Stock Is Down 5.10%
As of Monday, September 28, Carlsmed, Inc.’s CARL share price has dipped by 5.10%, which has investors questioning if this is right time to buy.Michael Rose
Why Carlsmed, Inc.’s (CARL) Stock Is Down 5.94%
As of Friday, August 21, Carlsmed, Inc.’s CARL share price has dipped by 5.94%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Is Carlsmed, Inc. (CARL) Overvalued?
We dive into why Carlsmed, Inc. (CARL) could be considered overvalued on 2026-08-17, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why Carlsmed, Inc.’s (CARL) Stock Is Up 9.44%
As of Thursday, August 06, Carlsmed, Inc.’s CARL share price has surged by 9.44%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CARL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $389.6 | $389.6 | 35% |
|
| Shares Out (Mil) | 27.2 | 40.9 | 35% |
|
| Institutional Ownership | 67.1% | 82.8% | 41% |
|
| Float (Mil) | 15.6 | 35.5 | 25% |
|
| Beta | na | 0.85 | na |
|
| Avg Daily Volume (000s) | 77 | 298 | 32% |
|
| Price Change (52-week) |
7.1% | 63.7% | 59% |
|
| Growth | CARL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | na | (5.6%) | na |
|
| EPS (5yr) | na | 10.2% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.5%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.385) | ($1.410) | ($1.380) | |
| Month Ago EPS | ($0.385) | ($1.410) | ($1.380) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.395) | ($1.465) | ($1.435) | |
| Year/Year Chg | (0.5%) | (33.6%) | (47.8%) | |
| Financials | CARL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $63 | $141 | 22% |
|
| Net Income (TTM) (Mil) | ($36) | ($9) | 19% |
|
| EPS (TTM) | ($1.425) | ($0.400) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($34) | ($2) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $13 | $1 | 58% |
|
| Long-Term Debt (Q1) (Mil) | $21 | $26 | 33% |
|
| Enterprise Value (Q1) (Mil) | $371 | $409 | 31% |
|
| Valuation | CARL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.62 | 2.73 | 77% |
|
| P/E | na | 25.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | CARL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 76.6% | 58.7% | 86% |
|
| Net Margin | (57.4%) | (6.9%) | 11% |
|
| ROA | (42.4%) | (12.2%) | 13% |
|
| ROE | na | (10.7%) | na |
|
| Liabilities to Assets | 28.7% | 47.2% | 20% |
|
| F-Score | 3 | 4 | 18% |
|
Carlsmed, Inc. did not pass any screens on 10/2/2026.
